If you buy inputs for cannabis or hemp products, the April rescheduling order is worth reading properly rather than through headlines, because what it did is narrower and stranger than the coverage implied.
What actually moved
The DOJ final rule at 91 FR 22714, effective 28 April 2026, orders:
“that FDA-approved drug products containing marijuana, as well marijuana in any form covered by a state medical marijuana license, be placed in schedule III of the CSA.”
And states, in the same document:
“any form of marijuana other than in an FDA-approved drug product or marijuana subject to a state medical marijuana license remains a schedule I controlled substance”
Adult-use cannabis is unchanged. That is the single most important line for commercial planning and the one most often omitted.
Why this splits your customer base
If you supply inputs into cannabis manufacturing, your customers now sit in three positions rather than one.
State medical licensees are handling Schedule III material. Adult-use operators are handling Schedule I material. Operators doing both have material in both categories depending on which licence covers it.
The order also establishes an expedited registration process under 21 CFR part 1301 for entities holding state medical marijuana licences, and adds these drugs to the list of substances importable or exportable only under permit.
The tax question, stated carefully
Section 280E follows the schedule, so rescheduling raises an obvious question about deductibility. The final rule does not answer it. It says licensees “should consult with tax counsel regarding the applicability of Section 280E to their specific circumstances”. Treasury and the IRS indicated on 23 April 2026 that they intended to issue guidance.
We would not build a commercial forecast on an outcome the issuing agency declined to state. If margin does improve for medical licensees, the reasonable expectation is more room for quality-led inputs over lowest-cost ones, but that is a directional expectation rather than a planning assumption.
What this does not change
Terpene supply is not directly affected. Terpenes are not scheduled controlled substances and the order concerns the classification of marijuana. Nothing here alters how aromatic inputs are bought, shipped or documented.
Nor does it interact with the hemp change. The November hemp deadline comes from a different statute and moves in the opposite direction. Conflating the two produces wrong answers to both, and we see it constantly.
Practical implications for sourcing
Know which of your customers are medical-licensed and which are adult-use, because their federal position and likely trajectory now differ.
If you supply both, expect divergence in what they can afford and how quickly they move. Expect more documentation requests from the medical side as registration processes bed in, since a business newly operating under federal registration tends to tighten its own supplier requirements in turn.
This is a reasonable moment to review whether your agreements handle regulatory change sensibly, particularly around exclusivity and term. Exclusive and non-exclusive arrangements carry different risk when the regulatory ground is moving, and the commercial structure of supply terms is worth revisiting rather than rolling over.
What is still pending
Rescheduling all marijuana remains in DEA administrative proceedings, with a hearing that began 29 June 2026 after the earlier 2024 proceedings were withdrawn and restarted. There is no guaranteed outcome and no published completion date. Plan for the split that exists today.
About this brief
Written 13 July 2026 and checked against the statute and the Federal Register rather than against secondary coverage. This is a summary for commercial planning, not legal advice. Where the answer depends on your product format, your state or your licence position, take the specific question to your own counsel.
